<?xml version='1.0' encoding='utf-8'?>
<document id="12515739"><sentence text="Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction."><entity charOffset="0-12" id="DDI-PubMed.12515739.s1.e0" text="Atorvastatin" /><entity charOffset="36-47" id="DDI-PubMed.12515739.s1.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.12515739.s1.e0" e2="DDI-PubMed.12515739.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12515739.s1.e0" e2="DDI-PubMed.12515739.s1.e1" /></sentence><sentence text="We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggregation with coadministration of atorvastatin during point-of-care platelet function testing"><entity charOffset="29-40" id="DDI-PubMed.12515739.s2.e0" text="clopidogrel" /><entity charOffset="120-132" id="DDI-PubMed.12515739.s2.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.12515739.s2.e0" e2="DDI-PubMed.12515739.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12515739.s2.e0" e2="DDI-PubMed.12515739.s2.e1" /></sentence><sentence text=" Because atorvastatin is metabolized by cytochrome P450 (CYP) 3A4, we hypothesized that clopidogrel might be activated by CYP3A4"><entity charOffset="9-21" id="DDI-PubMed.12515739.s3.e0" text="atorvastatin" /><entity charOffset="88-99" id="DDI-PubMed.12515739.s3.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.12515739.s3.e0" e2="DDI-PubMed.12515739.s3.e0" /><pair ddi="false" e1="DDI-PubMed.12515739.s3.e0" e2="DDI-PubMed.12515739.s3.e1" /></sentence><sentence text="" /><sentence text="Platelet aggregation was measured in 44 patients undergoing coronary artery stent implantation treated with clopidogrel or clopidogrel plus pravastatin or atorvastatin, and in 27 volunteers treated with clopidogrel and either erythromycin or troleandomycin, CYP3A4 inhibitors, or rifampin, a CYP3A4 inducer"><entity charOffset="108-119" id="DDI-PubMed.12515739.s5.e0" text="clopidogrel" /><entity charOffset="123-134" id="DDI-PubMed.12515739.s5.e1" text="clopidogrel" /><entity charOffset="140-151" id="DDI-PubMed.12515739.s5.e2" text="pravastatin" /><entity charOffset="155-167" id="DDI-PubMed.12515739.s5.e3" text="atorvastatin" /><entity charOffset="203-214" id="DDI-PubMed.12515739.s5.e4" text="clopidogrel" /><entity charOffset="226-238" id="DDI-PubMed.12515739.s5.e5" text="erythromycin" /><entity charOffset="242-256" id="DDI-PubMed.12515739.s5.e6" text="troleandomycin" /><entity charOffset="280-288" id="DDI-PubMed.12515739.s5.e7" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e0" e2="DDI-PubMed.12515739.s5.e0" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e0" e2="DDI-PubMed.12515739.s5.e1" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e0" e2="DDI-PubMed.12515739.s5.e2" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e0" e2="DDI-PubMed.12515739.s5.e3" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e0" e2="DDI-PubMed.12515739.s5.e4" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e0" e2="DDI-PubMed.12515739.s5.e5" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e0" e2="DDI-PubMed.12515739.s5.e6" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e0" e2="DDI-PubMed.12515739.s5.e7" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e1" e2="DDI-PubMed.12515739.s5.e1" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e1" e2="DDI-PubMed.12515739.s5.e2" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e1" e2="DDI-PubMed.12515739.s5.e3" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e1" e2="DDI-PubMed.12515739.s5.e4" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e1" e2="DDI-PubMed.12515739.s5.e5" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e1" e2="DDI-PubMed.12515739.s5.e6" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e1" e2="DDI-PubMed.12515739.s5.e7" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e2" e2="DDI-PubMed.12515739.s5.e2" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e2" e2="DDI-PubMed.12515739.s5.e3" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e2" e2="DDI-PubMed.12515739.s5.e4" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e2" e2="DDI-PubMed.12515739.s5.e5" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e2" e2="DDI-PubMed.12515739.s5.e6" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e2" e2="DDI-PubMed.12515739.s5.e7" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e3" e2="DDI-PubMed.12515739.s5.e3" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e3" e2="DDI-PubMed.12515739.s5.e4" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e3" e2="DDI-PubMed.12515739.s5.e5" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e3" e2="DDI-PubMed.12515739.s5.e6" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e3" e2="DDI-PubMed.12515739.s5.e7" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e4" e2="DDI-PubMed.12515739.s5.e4" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e4" e2="DDI-PubMed.12515739.s5.e5" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e4" e2="DDI-PubMed.12515739.s5.e6" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e4" e2="DDI-PubMed.12515739.s5.e7" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e5" e2="DDI-PubMed.12515739.s5.e5" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e5" e2="DDI-PubMed.12515739.s5.e6" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e5" e2="DDI-PubMed.12515739.s5.e7" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e6" e2="DDI-PubMed.12515739.s5.e6" /><pair ddi="false" e1="DDI-PubMed.12515739.s5.e6" e2="DDI-PubMed.12515739.s5.e7" /></sentence><sentence text=" Atorvastatin, but not pravastatin, attenuated the antiplatelet activity of clopidogrel in a dose-dependent manner"><entity charOffset="1-13" id="DDI-PubMed.12515739.s6.e0" text="Atorvastatin" /><entity charOffset="23-34" id="DDI-PubMed.12515739.s6.e1" text="pravastatin" /><entity charOffset="76-87" id="DDI-PubMed.12515739.s6.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.12515739.s6.e0" e2="DDI-PubMed.12515739.s6.e0" /><pair ddi="false" e1="DDI-PubMed.12515739.s6.e0" e2="DDI-PubMed.12515739.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12515739.s6.e0" e2="DDI-PubMed.12515739.s6.e2" /><pair ddi="false" e1="DDI-PubMed.12515739.s6.e1" e2="DDI-PubMed.12515739.s6.e1" /><pair ddi="false" e1="DDI-PubMed.12515739.s6.e1" e2="DDI-PubMed.12515739.s6.e2" /></sentence><sentence text=" Percent platelet aggregation was 34+/-23, 58+/-15 (P=0" /><sentence text="027), 74+/-10 (P=0" /><sentence text="002), and 89+/-7 (P=0" /><sentence text="001) in the presence of clopidogrel and 0, 10, 20, and 40 mg of atorvastatin, respectively"><entity charOffset="24-35" id="DDI-PubMed.12515739.s10.e0" text="clopidogrel" /><entity charOffset="64-76" id="DDI-PubMed.12515739.s10.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.12515739.s10.e0" e2="DDI-PubMed.12515739.s10.e0" /><pair ddi="false" e1="DDI-PubMed.12515739.s10.e0" e2="DDI-PubMed.12515739.s10.e1" /></sentence><sentence text=" Erythromycin attenuated platelet aggregation inhibition (55+/-12 versus 42+/-12% platelet aggregation; P=0"><entity charOffset="1-13" id="DDI-PubMed.12515739.s11.e0" text="Erythromycin" /></sentence><sentence text="002), as did troleandomycin (78+/-18 versus 45+/-18% platelet aggregation; P&lt;0"><entity charOffset="13-27" id="DDI-PubMed.12515739.s12.e0" text="troleandomycin" /></sentence><sentence text="0003), whereas rifampin enhanced platelet aggregation inhibition (33+/-18 versus 56+/-20% platelet aggregation, P=0"><entity charOffset="15-23" id="DDI-PubMed.12515739.s13.e0" text="rifampin" /></sentence><sentence text="001)" /><sentence text="" /><sentence text="CYP3A4 activates clopidogrel"><entity charOffset="17-28" id="DDI-PubMed.12515739.s16.e0" text="clopidogrel" /></sentence><sentence text=" Atorvastatin, another CYP3A4 substrate, competitively inhibits this activation"><entity charOffset="1-13" id="DDI-PubMed.12515739.s17.e0" text="Atorvastatin" /></sentence><sentence text=" Use of a statin not metabolized by CYP3A4 and point-of-care platelet function testing may be warranted in patients treated with clopidogrel"><entity charOffset="129-140" id="DDI-PubMed.12515739.s18.e0" text="clopidogrel" /></sentence><sentence text="" /></document>